Helicobacter pylori: Infection and New Perspective for the Treatment

The alarming phenomenon of antibiotic resistance in Helicobacter pylori suggests to pay close attention in the treatment. In particular, the clarithromycin resistance in H. pylori was designed by the World Health Organization (WHO) as high priority for antibiotic research in 2017 [1]. In Italy, the overall primary resistance to clarithromycin can be detected in 35.2% of cases; in France, it can be detected in 26% of cases, while in Spain, clarithromycin resistance is present in 27.2% of strains [2–4]. Natural/innovative strategies, as well as novel potentiators to restore the antibiotic susceptibility in resistant strains, could be used to improve the efficacy of H. pylori eradication, and …